JSR-LIFE-SCIENCES
JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to purchase Crown Bioscience International (TPEx: ticker 6554) at 12 Billion New Taiwan Dollar, a global drug discovery and development services company providing translational platforms to advanced oncology, inflammation, cardiovascular and metabolic disease research. This acquisition marks JSR’s largest life sciences-focused investment to date, extending the company’s portfolio to include industry-leading contract research and development capabilities, and ability to develop impactful solutions for pharma.
As a premier contract research organization (CRO), CrownBio has deep industry relationships and a global footprint that will complement JSR’s already global presence. Upon completion of the acquisition, JSR Life Sciences’ will enjoy a full suite of integrated capabilities that extend from pure research, to drug discovery, diagnostics development, cell line development and process development, through to GMP manufacturing.
“We are positioning to be the clear choice for innovation-driven strategic partnerships,” said Eric R. Johnson, President of JSR’s Life Sciences Division. “CrownBio, and its science-rich approach, is an ideal fit to support that goal. We’re bringing together innovative competencies that will lead to better solutions for pharma and improve their ability to take therapeutics to the market.”
As focus on personalized medicine continues to increase, CROs are turning into scientific leaders. Translational platforms, bioinformatics and modeling capabilities, like CrownBio’s patient-derived xenograft (PDX) models, are becoming fundamentally important to the development and commercialization of diagnostics and therapeutics. JSR’s forecast, based on consultation with CrownBio’s management team, is for the company to realize Revenue and EBITDA margin of 90 and 20 M USD respectively in 2018, with the understanding that such projected financial information may vary from actual results.
JSR has had extensive M&A activity in recent years. The 2015 majority interest acquisitions of contract development and manufacturing organization KBI Biopharma, Inc. and MBL Corporation, and the 2017 acquisition of mammalian cell line development pioneer Selexis SA, combine to be a strong technology engine for innovation.
JSR envisions that CrownBio’s development capabilities will enhance the contribution of JKiC, the company’s Japan-based industry-academia-medicine collaboration hub, by providing the tools and expertise to translate leading-edge research into tomorrow’s medicines.
About Crown Bioscience
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
About JSR Corporation
JSR Corporation is a multinational company with research-oriented organization that pursues close collaborations with leading innovators in a number of industries that are a key to the present and future welfare of human society: life sciences, synthetic rubbers, electronic materials, display and optical materials. JSR Corporation conducts its global life sciences business through its JSR Life Sciences Business Division. JSR Life Sciences provides specialized materials, products and services to the biotech industry both directly and through its subsidiaries Medical & Biological Laboratories Co. Ltd, KBI Biopharma, Inc. and Selexis SA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171220005165/en/
Contact:
JSR Life Sciences
Missy Bindseil, 1-830-237-9527
mbindseil@jsrlifesciences.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting samarbejder med MJB Technology Solutions om at fremme digitale transformationsmuligheder7.9.2025 08:24:00 CEST | Pressemeddelelse
Andersen Consulting styrker sin platform for digital transformation gennem et samarbejde med det canadiske firma MJB Technology Solutions, der er specialiseret i ServiceNow, kunstig intelligens, analyse og IT-transformation. MJB Technology Solutions blev stiftet i 2002 og udvikler skræddersyet software, digitale platforme og operationelle systemer til kunder inden for sektorer som banker, telekommunikation og produktion. Virksomhedens kernekompetencer omfatter komplekse ServiceNow-tjenester samt AI-baserede løsninger, business intelligence og analyse samt digital IT-strategi – og de leverer konsekvent målbare resultater og langsigtet værdi. "Gennem to årtier har vi leveret specialudviklede løsninger, der hjælper vores kunder med at tackle forretningskritiske udfordringer," siger Mark Bains, administrerende direktør hos MJB Technology Solutions. "Vores samarbejde med Andersen Consulting markerer et nyt kapitel i, hvordan vi skalerer innovation globalt, samtidig med at vi forbliver tro m
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease6.9.2025 02:45:00 CEST | Press release
− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative Management of Bleeding in Pediatric Patients with VWD1 − VONVENDI is the Only Recombinant Von Willebrand Factor Replacement Therapy with Approved Indications in Adults and Children with VWD1 − VWD, the Most Common Bleeding Disorder, Impacts More Than 3 Million People in the U.S.2 Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD. VONVENDI was previously approve
Samsung Unveils “AI Home: Future Living, Now” Vision at IFA 20255.9.2025 23:34:00 CEST | Press release
From well-being to energy efficiency, Bespoke AI, Vision AI, and Galaxy AI transform the way we live and connect. At Innovation For All (IFA) 2025, Samsung Electronics showcased its vision for “AI Home: Future Living, Now”. Samsung’s AI Home aims to be a reality people can experience today — not just in the future — and one designed for everyone, not just a select few. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905654772/en/ Cheolgi Kim, Head of Digital Appliances, presents Future Living Now at Samsung’s IFA 2025 press conference in Berlin “At Samsung, we’re not just imagining the future of AI; we’re building it into everyday life. Samsung’s AI Home moves beyond smart devices to homes that truly understand you, adapt to your needs, and care for what matters most,” said Cheolgi Kim (CK), Executive Vice President and Head of Digital Appliances (DA) Business. “This is the beginning of a new era - where technology support
Andersen Consulting styrker end-to-end-teknologikompetencer via samarbejde med FirstQA Systems5.9.2025 19:44:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation og kunstig intelligens via en samarbejdsaftale med FirstQA Systems, der er en førende teknologileverandør, som er kendt for sin ekspertise inden for AI til virksomheder, digital transformation og cybersikkerhed. FirstQA Systems K.K. med hovedsæde i Japan siden 2011 er en konsulentdrevet teknologivirksomhed, der betjener Fortune 500-virksomheder og multinationale koncerner i Asien, Europa og Nordamerika. Virksomheden specialiserer sig i kunstig intelligens, digital transformation (med fokus på platformene ServiceNow, SAP og Salesforce) samt it- og OT-cybersikkerhed. Gennem sit datterselskab, Himitsu Lab Limited, leverer FirstQA Systems banebrydende Agentic AI-løsninger drevet af HIMITSU8™ Unified Development Framework (UDF)™. Virksomhedens brancheekspertise dækker bl.a. produktion, medicinalindustrien samt løsninger til bank- og finansverdenen. "Vores samarbejde med Andersen Consulting markerer et spændende sk
NetApp named a Leader by Gartner® in the 2025 Magic Quadrant™ for Enterprise Storage Platforms5.9.2025 17:15:00 CEST | Press release
Recognition reflects NetApp’s Ability to Execute and Completeness of Vision NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2025 Gartner Magic Quadrant for Enterprise Storage Platforms. NetApp believes this recognition reflects how the company’s continuous innovation helps customers build Intelligent Data Infrastructure to face modern technology challenges, including protection from cyber threats and using AI to drive data-based decisions. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. According to Gartner, “Enterprise storage platforms offer platform-native service capabilities and product features for both structured and unstructured data workloads. Heads of infrastructure and operations should use this research to assess vendors in deploying a modern IT infrastructure platform for block, file and object storage.”
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom